Our Vaccines
Science
Vaxxilon was founded to develop synthetic carbohydrate vaccines. These vaccines are comprised of oligosaccharides (small fragments of naturally occurring carbohydrates) and the novel immune stimulator, alpha galactosylceramide. Two fundamental insights are the basis of this science:

Pipeline
Through the rationale design of synthetic carbohydrate vaccines, Vaxxilon aims to improve existing vaccines and create new ones faster and less expensively with benefits to patients, parents, and health care providers around the world. We are advancing several vaccine candidates and considering new projects to initiate.
Bacteria | Serotype | Vaccine Type | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 |
---|---|---|---|---|---|---|---|
Streptococcus pneumoniae | 3 | Semi-synthetic |
.
|
||||
Haemophilus influenzae type B | n/a | Semi-synthetic |
.
|
||||
Streptococcus pneumoniae | multiple, undisclosed | Semi-synthetic |
.
|
||||
Streptococcus pneumoniae | not disclosed | Fully-synthetic |
.
|
||||
Klebsiella pneumoniae | multiple | Semi-synthetic |
.
|
||||
2 additional targets | undisclosed |
.
|
Publications
Basel Area Vaxxilon AG Christoph Merian-Ring 11, 4153 Reinach, Switzerland
Berlin Area (Adlershof) Vaxxilon Deutschland GmbH Magnusstraße 11, 12489 Berlin, Germany